Bilal Farhat, MD
Ophthalmology · Wichita, KSNPI 1245645258
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations.
Across 88 payments — averaging $31.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$597
- Bausch & Lomb Americas Inc.$503
- Glaukos Corporation$383
- Alcon$350
- AbbVie$321
- Rayner Intraocular Lenses Limited$183
- plus $469 from 14 others
What the payments were for
- Food & beverage$2,78799%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 11 | $597 |
| Bausch & Lomb Americas Inc. | 11 | $503 |
| Glaukos Corporation | 8 | $383 |
| Alcon | 18 | $350 |
| AbbVie(2 entities) | 13 | $321 |
| Rayner Intraocular Lenses Limited | 2 | $183 |
| Sun Pharmaceutical Industries Inc. | 4 | $69 |
| The Cameron-ehlen Group, Inc. | 3 | $48 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $45 |
| Novartis | 2 | $43 |
| Carl Zeiss Meditec USA, Inc. | 2 | $40 |
| Dompe US, Inc. | 2 | $40 |
| Rxsight Inc | 2 | $39 |
| Sight Sciences, Inc. | 2 | $34 |
| Ocular Therapeutix, Inc. | 1 | $19 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Optos, Inc. | 1 | $18 |
| Aerie Pharmaceuticals, Inc. | 1 | $18 |
| Tarsus Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$262
- KXL System$245
- IACCESS$137
- iStent$137
- iStent inject W$137
- RayOne EMV$126
- RayOne Spheric$126
- RayOne Aspheric$126
- RESTASIS$125
- AmnioGraft$123
- PHOTREXA CROSS-LINKING KIT$108
How this compares
$2,807 in reported general payments places this provider in the 70th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 53 | $34,090 |
| Prednisolone Acetate | 346 | $16,585 |
| Cyclosporine | 11 | $9,323 |
| Difluprednate | 27 | $4,147 |
| Ketorolac Tromethamine | 255 | $3,865 |
| MoxifloxacinMoxifloxacin Hcl | 103 | $2,812 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $2,788 |
| ValacyclovirValacyclovir Hcl | 30 | $2,516 |
| Ofloxacin | 218 | $2,196 |
| Latanoprost | 90 | $974 |
| Fluorometholone | 15 | $808 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $253 |
| Doxycycline Hyclate | 19 | $182 |
| Timolol Maleate | 26 | $139 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 12 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $321 | $34,09053 claims |
| AlconSimbrinza | $350 | $2,78814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 135 ophthalmology providers in Kansas.
Other ophthalmology in Wichita
- Michele RigginsWichita$16K
- Finny JohnWichita$12K
- Reena PatelWichita$7K
- Jennifer BurgoyneWichita$4K
- Terria WinnWichita$3K
- Martin de la PresaWichita$2K
- Daniel DurrieOverland Park$974K
- John DoaneLeawood$496K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.